UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000032775
Receipt No. R000037321
Scientific Title An observational study on interaction between 5ASA and thiopurine in ulcerative colitis
Date of disclosure of the study information 2018/05/30
Last modified on 2021/12/02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title An observational study on interaction between 5ASA and thiopurine in ulcerative colitis
Acronym An observational study on interaction between 5ASA and thiopurine in ulcerative colitis
Scientific Title An observational study on interaction between 5ASA and thiopurine in ulcerative colitis
Scientific Title:Acronym An observational study on interaction between 5ASA and thiopurine in ulcerative colitis
Region
Japan

Condition
Condition Ulcerative colitis
Classification by specialty
Gastroenterology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 In this multicenter observational Study, we examine the effect on 6-TGN concentration in blood by changing the type of mesalazine in UC patient who used both mesalazine and thiopurine. And we also verify clinical efficacy and safety.
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Changes in blood 6-TGN concentration before and after changing the type of mesalazine
Key secondary outcomes Clinical efficacy and safety by changing the type of mesalazine

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients who diagnosed UC by Ministry of Health, Labor and Welfare Diagnostic criteria of research group on intractable inflammatory bowel disorder (revised version of 2016)
Patients who obtained informed consent of this clinical study
Patients 18 years of age or older
Patients who use both mesalazine and thiopurine
Patients who use thiopurine for 8 weeks or more, and have continued for the same amount for 4 weeks or more
Patients who have continued the same amount of mesalazine for 4 weeks or more
Patients who switch mesalazine formulations to other mesalazine drugs
Key exclusion criteria Patients after total colonectomy
Patients who are concurrently using uric acid synthesis inhibitors
Target sample size 50

Research contact person
Name of lead principal investigator
1st name Hiromu
Middle name
Last name Morikubo
Organization Kitasato University Kitasato Institute Hospital
Division name Center for Advanced IBD Research and Treatment
Zip code 108-8642
Address 5-9-1, Shirokane, Minato-ku, Tokyo, Japan
TEL 03-3444-6161
Email tomato0112@gmail.com

Public contact
Name of contact person
1st name Hiromu
Middle name
Last name Morikubo
Organization Kitasato University Kitasato Institute Hospital
Division name Center for Advanced IBD Research and Treatment
Zip code 108-8642
Address 5-9-1, Shirokane, Minato-ku, Tokyo, Japan
TEL 03-3444-6161
Homepage URL
Email tomato0112@gmail.com

Sponsor
Institute Kitasato University Kitasato Institute Hospital.
Institute
Department

Funding Source
Organization Kitasato University Kitasato Institute Hospital.
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Kitasato University Kitasato Institute Hospital Research Department Research Ethics Committee Secretariat
Address 5-9-1, Shirokane, Minato-ku, Tokyo, Japan
Tel 03-3444-6161
Email kenkyu@insti.kitasato-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 05 Month 30 Day

Related information
URL releasing protocol https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.15411?af=R
Publication of results Unpublished

Result
URL related to results and publications https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.15411?af=R
Number of participants that the trial has enrolled 50
Results Results
Plasma 5-ASA and N-Ac-5-ASA levels were significantly higher in patients receiving time-dependent mesalazine (n = 12) compared with pH-dependent mesalazine (n = 12) and MMX (n = 15), accompanied by greater TPMT inhibition. Prospective switching from time-dependent mesalazine to MMX decreased 6-TGN levels, increased those of 6-MMP, and increased 6-MMP/6-TGN ratios. Furthermore, this resulted in significantly more relapses than switching from pH-dependent mesalazine to MMX.
Results date posted
2021 Year 12 Month 02 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics Thiopurines are often used in combination with mesalazine for the treatment of ulcerative colitis (UC). Mesalazine formulations are delivered to the digestive tract by various delivery systems and absorbed as 5-aminosalicylic acid (5-ASA). 5-ASA is known to inhibit thiopurine S-methyltransferase (TPMT) activity and to affect thiopurine metabolism. There have been no studies comparing TPMT inhibition by multimatrix mesalazine (MMX) with other formulations.
Participant flow We investigated the difference in TPMT inhibition by different mesalazine formulations and prospectively confirmed the clinical relevance.
Adverse events None
Outcome measures Changes in the concentration of 6TGN before and after the change of 5-ASA
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 11 Month 17 Day
Date of IRB
2017 Year 11 Month 17 Day
Anticipated trial start date
2017 Year 11 Month 27 Day
Last follow-up date
2019 Year 12 Month 31 Day
Date of closure to data entry
2020 Year 12 Month 31 Day
Date trial data considered complete
Date analysis concluded

Other
Other related information Primary outcomes: Changes in blood 6-TGN concentration before and after changing the type of mesalazine
Secondary outcomes: Clinical efficacy and safety by changing the type of mesalazine

Management information
Registered date
2018 Year 05 Month 30 Day
Last modified on
2021 Year 12 Month 02 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037321

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.